United Therapeutics Corp - Company Profile
Powered by 
All the sales intelligence you need on United Therapeutics Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how United Therapeutics Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with United Therapeutics Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
United Therapeutics Corp (United Therapeutics) is a biotechnology company focused on the development and commercialization of pharmaceutical therapies and technologies aimed at treating rare and life-threatening diseases. The company primarily serves the healthcare and pharmaceutical industries, with a focus on pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and neuroblastoma. The company’s products portfolio includes Tyvaso DPI, Nebulized Tyvaso, Remodulin, Remunity and RemunityPRO Pumps for Remodulin, Orenitram, Unituxin and Adcirca.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
United Therapeutics's R&D arm focuses on developing new indications and delivery devices for existing products, particularly in the areas of pulmonary arterial hypertension (PAH) and pulmonary hypertension-associated with interstitial lung disease (PH-ILD). The company is conducting clinical trials such as the TETON studies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), and the ADVANCE OUTCOMES study for ralinepag in PAH. Additionally, United Therapeutics is exploring technologies to increase the supply of transplantable organs and improve outcomes for transplant recipients through xenotransplantation, regenerative medicine, and ex vivo lung perfusion. The R&D units of United Therapeutics include facilities in Eden Prairie, Minnesota, and Manchester, New Hampshire. The Minnesota facility focuses on producing manufactured kidney and liver products for research and development purposes and clinical trials, while the New Hampshire facility conducts 3D organ alternative bioprinting research and development activities. In FY2025, the company spent US$550 million on its R&D, which as a percentage of revenue stood at 17.3% and grew 14% YoY.
Product Categories
Overview
It is an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil to improve exercise ability in PAH patients. Sold in the US.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is a liquid inhaled formulation of treprostinil to improve exercise ability in patients with PH-ILD. Sold in Asia, the Middle East, and Latin America.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is an oral extended-release tablet form of treprostinil that delays disease progression and improves exercise capacity in PAH patients. Sold in the US.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers Remunuity pump for remodulin.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is a continuously infused formulation of treprostinil for subcutaneous and intravenous delivery to diminish symptoms associated with exercise in patients with PAH. Sold in in the U.S., most of Europe, Japan, and various other countries in Asia, the Middle East, and Latin America.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is a dry powder inhaled formulation of the prostacyclin analogue treprostinil to improve exercise ability in patients with pulmonary arterial hypertension (PAH) and PH-ILD. Primarily sold in the US.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is an infused monoclonal antibody approved in the US and Canada for the treatment of high-risk neuroblastoma and approved in Japan for the treatment of neuroblastoma after high-dose chemotherapy.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer